Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Daniel_Barber
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedBy |
pharmaceutical films
|
| gptkbp:focusesOn |
pharmaceutical development
oral drug delivery |
| gptkbp:formerName |
gptkb:MonoSol_Rx
|
| gptkbp:foundedYear |
2004
|
| gptkbp:headquartersLocation |
gptkb:Warren,_New_Jersey,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Aquestive Therapeutics
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:notableProduct |
gptkb:Exservan
gptkb:Suboxone_(film_formulation) gptkb:Sympazan |
| gptkbp:numberOfEmployees |
approximately 150 (as of 2023)
|
| gptkbp:publiclyTraded |
gptkb:NASDAQ
|
| gptkbp:specializesIn |
proprietary PharmFilm technology
|
| gptkbp:stockSymbol |
gptkb:AQST
|
| gptkbp:website |
https://www.aquestive.com/
|
| gptkbp:bfsParent |
gptkb:Exservan
|
| gptkbp:bfsLayer |
6
|